Medication info

CeBITera 5/20 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›20mg / 1 tablet
Manufacturer / importer
Teragen Etex Co., Ltd.
Appearance
White, round, film-coated tablets
Packaging
30 tablets/PPT [10 tablets/PPT x 3]
Approval status
Expired

MFDS item code 202002845 · Approved 2020.04.22

This product's status changed to Expired on 2025.04.22. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension
Who takes it
Adults · Children
Adult dose
Administer 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take the medicine at the same time every day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using an individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘ Patients with reduced effective circulating blood volume: In patients who may have reduced effective circulating blood volume (Intravascular volume depletion) (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. ∘ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients Who Should Not Receive This Medicine under Precautions for Use.) ∘ Older adults: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In older adults, blood pressure should be monitored closely and more frequently.
Child dose
∘ Children: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Teragen Etex Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Essential hypertension
View approved original text

Amlodipine or Olmesartan Medoxomil is used in patients with essential hypertension. These drugs help in treatment when blood pressure is not adequately controlled with monotherapy. They effectively lower blood pressure, reducing the risk of cardiovascular complications, and assist in stable blood pressure control. Consistent use contributes to hypertension management and plays an important role in improving patients' health. These drugs are used to treat essential hypertension.

How to take

Adult dose

Administer 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take the medicine at the same time every day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using an individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘ Patients with reduced effective circulating blood volume: In patients who may have reduced effective circulating blood volume (Intravascular volume depletion) (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. ∘ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients Who Should Not Receive This Medicine under Precautions for Use.) ∘ Older adults: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In older adults, blood pressure should be monitored closely and more frequently.

Child dose

∘ Children: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause severe harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, if pregnancy is confirmed, it must be discontinued immediately. Patients with allergies to the main ingredient or similar components, those who are pregnant or breastfeeding, individuals with severe hepatic disease or aortic stenosis, patients with bile duct obstruction, those undergoing renal dialysis, individuals in a state of shock, and certain diabetic patients should not take this medication. Caution is necessary when administering this drug to patients with hypotension from fluid or sodium depletion, those at risk of sudden vasodilation, patients with severe obstructive coronary artery disease or congestive heart failure, poor kidney function, and impaired liver function, and they should be closely monitored. Side effects such as dizziness, headache, hypotension, edema, dyspepsia, and rash may occur while taking this medication, and in rare cases, serious side effects may occur. Patients should consult medical professionals immediately if unusual symptoms appear. Unlike beta-blockers, this medication poses less risk when suddenly discontinued; however, there are potential interactions when used in conjunction with other antihypertensive drugs, so it should be taken according to the physician's instructions. This medication should not be used during pregnancy, and if planning to become pregnant, it is advisable to switch to other drugs that have verified safety. Breastfeeding mothers should be aware that this medication can pass into breast milk and may affect the baby; therefore, it is recommended to either stop breastfeeding or discontinue the medication. The safety and efficacy of this medication have not been established in children or adolescents under 18 years of age, so it is best not to use it in these populations. For the elderly, renal and hepatic functions may be impaired, so it is recommended to start with a lower dose and monitor their condition closely. Overdose may result in hypotension and impaired cardiac function, requiring immediate medical attention for proper treatment. This medication should be stored away from direct sunlight and moisture in a sealed container, and it is advisable not to transfer it to another container.

Side effects

Drug hypersensitivity, hyperkalemia, decreased libido, dizziness, headache, orthostatic hypotension, drowsiness, paresthesia, sensory impairment, syncope, lightheadedness, palpitations, tachycardia, hypotension, orthostatic hypotension, dyspnea, cough, nausea, vomiting, dyspepsia, diarrhea, constipation, dry mouth, upper abdominal pain, rash, urticaria, muscle tension, limb pain, low back pain, polyuria, erectile dysfunction, peripheral edema, edema, dependent edema, fatigue, asthenia, facial swelling, decreased blood potassium, increased serum creatinine, increased serum uric acid, increased gamma-glutamyl transferase, decreased hemoglobin and hematocrit, cholelithiasis, female breast neoplasm, exacerbation of cerebral infarction, gum bleeding, chest pain, cold, increased CRP, fever, hemoptysis, excessive sneezing, runny nose, laryngitis, arthritis, flank pain, generalized pain, hypoglycemia, weight loss, heartburn, gastroenteritis, herpes zoster, diplopia, insomnia, asthenia, vascular edema, chronic malabsorption syndrome - similar intestinal disease, rhabdomyolysis, acute renal failure, hair loss, itching, autoimmune hepatitis, flushing, fatigue, edema, palpitations, lightheadedness, headache, drowsiness, abdominal pain, nausea, gynecomastia, jaundice, liver enzyme elevation, leukopenia, thrombocytopenia, toxic epidermal necrolysis, hypotension, tachycardia, bradycardia, non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture; therefore, it should be stored in a sealed container. It is recommended to maintain a room temperature between 1 to 30 degrees Celsius to preserve the drug’s effectiveness for a longer duration.

Appearance and packaging

Appearance

White, round, film-coated tablets

Package unit

30 tablets/PPT [10 tablets/PPT x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.